MAX Chat
Share chart BioMarin Pharmaceutical
Extended chart
Simple chart
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. — американская биотехнологическая компания со штаб-квартирой в Сан-Рафаэле, Калифорния . У него есть офисы и помещения в США , Южной Америке , Азии и Европе . Основным направлением деятельности и исследованиями BioMarin является заместительная терапия ферментами (ФЗТ). BioMarin была первой компанией, которая предоставила терапевтические средства для лечения мукополисахаридоза типа I (MPS I), производя ларонидазу ( Aldurazyme , коммерциализируется Genzyme Corporation). BioMarin также была первой компанией, которая начала предлагать препараты для лечения фенилкетонурии.
Main settings
IPO date
1999-07-23
ISIN
US09061G1013
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 4.51 | 3 |
| P/BV | 2.28 | 6 |
| P/E | 30.16 | 5 |
Efficiency
| Title | Value | Grade |
| ROA | 6.17 | 2 |
| ROE | 8.05 | 3 |
| ROIC | 0.79 | 1 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 0.9265 | 9 |
| Debt/Ratio | 0.0862 | 10 |
| Debt/Equity | 0.2352 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 53.44 | 7 |
| Yield Ebitda, % | -11125.9 | 0 |
| Yield EPS, % | -51.56 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 57.28 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 56.65 $ | 0 $ | 0 $ | +1.11 % | 0 % | 0 % |
| Month | 58.01 $ | 0 $ | 0 $ | -1.26 % | 0 % | 0 % |
| Three month | 59.43 $ | 55.27 $ | 63.69 $ | -3.62 % | 0 % | 0 % |
| Half a year | 62.87 $ | 55.27 $ | 72.83 $ | -8.89 % | 0 % | 0 % |
| Year | 90.46 $ | 55.27 $ | 93.84 $ | -36.68 % | 0 % | 0 % |
| 3 years | 89.02 $ | 55.27 $ | 117.27 $ | -35.65 % | 0 % | 0 % |
| 5 years | 78.74 $ | 55.27 $ | 124 $ | -27.25 % | 0 % | 0 % |
| 10 years | 81.38 $ | 55.27 $ | 146.27 $ | -29.61 % | 0 % | 0 % |
| Year to date | 61.53 $ | 55.27 $ | 72.83 $ | -6.91 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| VictoryShares Nasdaq Next 50 ETF | 1.38305 | 4.94 | 0.18 |
| iShares Evolved U.S. Innovative Healthcare ETF | 1.35 | 0.000586 | 0.18 |
| Future Tech ETF | 1.30612 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 1.30612 | -3.92 | 0.35 |
| IQ Engender Equality ETF | 1.03522 | 3.37 | 0.45 |
| GraniteShares XOUT U.S. Large Cap ETF | 0.86381 | -24.16 | 0.60 |
| Syntax Stratified MidCap ETF | 0.34133 | -0.3413 | 0.35 |
| iShares Morningstar Mid-Cap Growth ETF | 0.24673 | 450.65 | 0.06 |
| iShares Morningstar Mid-Cap ETF | 0.12333 | 245.03 | 0.04 |
| iShares Morningstar Large-Cap Growth ETF | 0.05463 | 245.22 | 0.04 |
| iShares Morningstar Large-Cap ETF | 0.0266 | 186.3 | 0.03 |
| Columbia U.S. ESG Equity Income ETF | 0.02348 | -4.51 | 0.35 |
| 0.67 | 131.84 | 0.25 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Brian R. Mueller | CFO & Executive VP | 1.15M | 1974 (51 year) |
| Mr. George Eric Davis | Executive VP, Chief Legal Officer, General Counsel & Secretary | 1.23M | 1971 (54 years) |
| Ms. Erin Burkhart | Group VP & Chief Accounting Officer | N/A | 1979 (46 years) |
| Mr. Alexander Hardy | President, CEO & Director | N/A | 1969 (56 years) |
| Dr. C. Greg Guyer Ph.D. | Executive VP & CTO | 1962 (63 years) | |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development | ||
| Traci McCarty | Group Vice President of Investor Relations | ||
| Ms. Humaira Serajuddin | Senior VP & Chief Marketing Officer | ||
| Ms. Amy Wireman | Executive VP & Chief People Officer |
About company
Address: United States, San Rafael, 770 Lindaro Street - Open in google maps, Open in yandex maps
Website: http://www.biomarin.com
Website: http://www.biomarin.com
